32. Wiedmann T. S. DeCastro L. Wood R.W. (1997) Pharm. Res. 14, 112-116.
33. Muller R.H., Peters K., Becker R., Kruss B. (1996) Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22, 574-575.
34. Bohm B.H.L., Grau M.J., Hildebrand G.E., et al. (1998) Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 25, 956-957.
35. Allen T.M. (1997) Drugs, 54, Suppl. 4, P. 8-14.
36. Torchilin V.P. (1996) Mol. Med. Today, 2, 242-249.
37. Torchilin V.P. (1996) J. Mol. Recognit. 9, 335-346.
38. Dass C.R., Walker T.L., Burton M.A., Decruz E.E. (1997) J. Pharm. Pharmacol. 49, 972-975.
39. Aliсo S.F. (1997) Biochem. Pharmacol. 54, 9-13.
40. Жданов Р.И. Куценко Н.Г. Федченко В.И. (1997) Вопр. мед. химии 43, 3-12
41. Тараховский Ю.С., Иваницкий Р.Г. (1998) Биохимия. 63, 723-736.
42. Yang K., Clifton G.L., Hayes R.L. (1997) J. Neurotrauma. 14, 281-297.
43. Hirnle P. (1997) Hybridoma. 16, 127-132.
44. Rongen H.A., Bult A., van Bennekom W.P. (1997) J. Immunol. Methods. 204, 105-133.
45. Devine D.V., Marjan J.M. (1997) Crit. Rev. Ther. Drug Carrier Syst. 14, 105-131.
46. Imai E., Isaka Y., Akagi Y., Kaneda Y. (1997) Exp. Nephrol. 5, 112-117.
47. Morishita R., Higaki J., Aoki M., et al. (1996) Contrib. Nephrol. 118, 254-264.
48. Schmid M.H., Korting H.C. (1994) Crit. Rev. in Ther. Drug Carrier Syst., 11, 97-118.
49. Sharata H.H., Katz K.H. (1996) Int. J. Dermatol., 35, 761-769.
50. Cevc G., Crit. Rev. (1996) Ther. Drug Carrier Syst., 13, 257-388.
51. Yuan F., Dellian M., Fukumura D.F. et al. // Cancer Res.1995. V. 55. P. 3752.
52. Lasic D.D., Papahadjopoulos D. // Science. 1995. V. 267. P. 1275.
53. Gabizon A., Schmeeda H., Barenholz Y. // Clin. Pharmacokinet. 2003. V. 42. P. 419.
54. Водовозова Е.Л., Никольский П.Ю., Михалев И.И. и др. // Биоорган. химия. 1996. Т. 22. С. 548.
55. Водовозова Е.Л., Евдокимов Д.В., Молотковский Юл.Г. // Биоорган. химия. 2004. Т. 30. С. 663.
56. Водовозова Е.Л., Кузнецова Н.Р., Кадыков В.А. // Рос. нанотехнологии. 2008. Т. 3. С. 162.
57. Alberts D.S., Muggia F.M., Carmichael J. et al. // Semin. Oncol. 2004. V. 31. P. 53.
58. Kuznetsova N., Kandyba A., Vostrov I. et al. // J. Drug Deliv. Sci. Technol. 2009. V. 19. P. 51.
59. Козлов А.М., Корчагина Е.Ю., Водовозова Е.Л. и др. // Бюлл. экспер. биол. мед. 1997. Т. 123. С. 439.
60. VodovozovaE.L., MoiseevaE.V., GrechkoG.K. etal.// Eur. J. Cancer. 2000. V. 36. P. 942.
61. Torchilin VP. (2006)Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
62. Kimball's Biology Pages, "Cell Membranes."
63. Stryer S. (1981) Biochemistry, 213
64. Barani, H. & Montazer, M. (2008) A Review on Applications of Liposomes in Textile Processing. Journal of Liposome Research, 18 (3) 249-262
65. Meure, L.A., Knott, R., Foster, N.R., Dehghani, F. (2009) The Depressurization of an Expanded Solution into Aqueous Media for the Bulk Production of Liposomes. Langmuir, 25, 326-337
66. L Zhang, FX Gu, JM Chan, AZ Wang, RS Langer and OC Farokhzad (2008). "Nanoparticles in Medicine: Therapeutic Applications and Developments". Clinical Pharmacology and Therapeutics 83 (5): 761-69. doi:10.1038/sj.clp t.6100400. PMID 17957183. http://www.nature.com/clpt/journal/v83/n5/full/6100400a.html.
67. Gomez-Hens, A., Fernandez-Romero, J.M. (2006). Analytical methods for the control of liposomal delivery systems. Trends Anal Chem 25:167–178.
68. Mozafari, M.R., Johnson, C., Hatziantoniou, S. & Demetzos, C. (2008) Nanoliposomes and their applications in food nanotechnology. Journal of Liposome Research. 18 (4), 309-327.
69. Mozafari, M.R. & Mortazavi, S.M. (2005) Nanoliposomes: From Fundamentals to Recent Developments. Trafford Publishing Ltd, Oxford, UK.
70. Colas, J.C., Shi, W.L., Rao, V.S.N.M., Omri, A., Mozafari, M.R., Singh, H. (2007) Microscopical investigations of nisin-loaded nanoliposomes prepared by Mozafari method and their bacterial targeting. Micron 38:841–847.
71. Lasic D.D., Papahadjopoulos D. Liposomes revisited: Science. 1995; 267: 1275–6.
72. Harrington K.L., Lewanski C.R., Stewart S.W. Liposomes as vehicles for targeted therapy of cancer/Part.2: Clinical development. Clin Oncol 2000; 12: 16–24.
73. Maruyama К. In vivo targeting by liposomes. Biol Pharm Bull 2000; 23: 791–9.
74. Wright S., Huang L. Advanced Drug Delivery Rev 1989; 3: 343–40.
75. Torchilin V.P., Klibanov A.L., Huang L. et al. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 1992; 6: 2716–9.
76. Torchilin V.P., Papisov M.I., Bogdanov A.A. et al. Molecular mechanissm of liposome and immunoliposome steric protection with poly(ethylene glycol) in "Stealth Liposomes". D.Lasic, F.Martin (Eds), P.51-62. CRC Press<Boca Raton. FL. 1995.
77. Alien T.M., Brandeis E., Hansen C.B. et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995; 1237: 99–108.
78. Lopes de Menezes D.E., Pilarski L.M., Belch A.R., Alien T.M. Selective targeting of immunoliposomal doxorobicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000; 1466 (1-2): 205–20.
79. Kirpotin D., Park J.W., Hong K. et al. Sterically stadilized anti-HER2 immunoliposomes: desin and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36: 66–75.
80. Park J.W., Hong K., Kirpotin D.B., Papahandjopoulos C.C., Benz C.C. Adv Pharmacol 1997; 40: 399–435.
81. Papahadjopoulos D., Kilpotin D.B., Park J.W., Hong K., Yi Shao, Shalaby R., Colbern G., Benz C.C. Targeting of drugs to solid tumors using anti-HER2 immunoliposomes. J Liposome Research 1998; 8 (4): 425–42.
82. Dufresne I., Desormeaux A., Bestman-Smith J., Gourde P., Tremblay M.J., Bergeron M.G. Targeting lymph nodes with liposomes bearing anti-HLA-GR Fab' fragments. Biochim Biophys Acta 1999; 1421 (2): 284–94.
83. Bestman-Smith J., Gourde P., Desormeaux A., Tremblay M.J, Bergeron M.G. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim Biophys Acta 2000; 1468 (1-2); 161–74.
84. Lundberg B.B., Griffiths G., Hansen H.J. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int J Pharm 2000; 205 (1-2): 101–8.
85. Merrcadal M., Domingo J.C., Petriz J., Garcia J., de Madariaga M.A. Preparation of immunoliposomes bearing poly(ethylene glycol)-coupied monoclonal antibody linked via a clevable disulfide bond for ex vivo applications. Biochim Biophis Acta 2000; 1509: 299–310.
86. Park S., Durst R.A Immunoliposoine sandwich assay for the detection of Escherichia coli 0157:H7. Anal Biochem 2000; 280 (1): 151–8.